HIV Active in Tissues of Patients Who Received Antiretroviral Treatment, Study Shows

While successful treatment of HIV with antiretroviral medications leads to undetectable levels of virus in the blood, controls the disease and leads to much longer lifespans, scientists know that HIV continues to reside in tissues.

Now, UC San Francisco researchers have found in autopsy tissue samples of patients treated with antiretrovirals that the virus evolved and migrated among tissues similar to the way it did in patients who had never received antiretroviral treatment, despite the fact that the treated patients had undetectable levels of virus in their blood.

The new study, the researchers said, supports the likelihood that the virus may at least be contributing to the development of non-AIDS-defined diseases, such as cancer and cardiovascular disease.

“Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals. Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications. While this is expected in untreated patients, it was a surprise to see this in virally suppressed patients. Our results suggest that HIV in varied tissue compartments can be untouched by the medications,” said study senior author, Michael S. McGrath, MD, PhD, UCSF professor of laboratory medicine at the AIDS and Cancer Specimen Resource at UCSF. 

The research is published in the October 2016 issue of The Journal of Virology and was selected by the editors as a “Spotlight” article of significant interest.

The tissues examined by the research team came from the National Cancer Institute-supported AIDS and Cancer Specimen Resource at UCSF, which contains samples collected from patients beginning in 1984.

“Our findings suggest the spectrum of ‘non-AIDS defining’ diseases such as cancers and cardiovascular disease that are increasingly the cause of death for virally suppressed patients are likely driven to some degree by the presence of active, untreated virus in tissues,” said McGrath. “In addition, our findings suggest that strategies to ‘cure’ HIV infection, which are centered on treatment of blood, must consider targeting tissue based sites of HIV.”

In these studies, the team examined mutations in HIV genetic sequences from patient’s tissues. HIV that continues to replicate and spread shows genetic changes in viral sequences that can only occur if the virus is replication competent and capable of spreading. In patients without antiretroviral treatment, this analysis can reveal if and how much the virus is evolving, a phenomenon typically observed in HIV infection without treatment. HIV replication and evolution is inhibited by antiretroviral therapy, and genetic sequencing of HIV from virally suppressed patients reflects the inhibitory effects of therapy.

In the current study, researchers looked at HIV from tissues taken from five HIV-infected patients who had been treated with antiretroviral therapy, had no detectable virus in the blood and who had died from cancer, and compared it to HIV sequence changes taken from patients who had never received therapy and also had died from cancer.

“The evolution of HIV derived from both treated and untreated patients’ tissues, which showed no evidence for an antiretroviral effect, stood in sharp contrast to other researchers’ findings from blood studies of patients treated with antiretrovirals showing dramatic drops in both the number of HIV particles and evolution of the virus, confirming a predominant blood effect of antiretroviral therapy unappreciated prior to the current study,” added McGrath.

The research team found evolving “wild type” HIV, that is virus unaffected by antiretroviral therapy, in the cerebellum, lymph nodes, lungs, colons and spleens among others tissues.

The team also pointed to a role for HIV-infected macrophages, a long-lived tissue-based immune cell that engulfs and destroys cellular debris, foreign substances, microbes, and cancer cells, in disease progression. “Tissue macrophages, activated due to HIV infection, can turn on or contribute to disease processes, such as cardiovascular disease and neurological disease,” said McGrath.

Co-authors include Rebecca Rose, Susanna L. Lamars and David J. Nolan from Bioinfoexperts LLC, Thibodaux, Louisiana; N. R. Faria and Oliver G. Pybus from the University of Oxford, United Kingdom; James J. Dollar, Samuel A. Maruniak, Andrew C. McAvoy and Marco Salemi from the University of Florida; Elyse J. Singer from UCLA; and Ekaterina Maidji and Cheryl Stoddart, PhD, from UCSF.

This research was funded by the National Institutes of Health, the National Cancer Institute (UM1 CA181255) and the National Institute of Mental Health (NIH R01 MH100984) and (NIMH U24MH100929).

The AIDS and Cancer Specimen Resource (ACSR) at UCSF is a resource for investigators working in the fields of HIV/AIDS, cancer, virology, immunology, pathology, epidemiology, tumor biology assay development, and many others. It is a biorepository for HIV-infected human biospecimens from a wide spectrum of HIV-related or associated diseases, including cancer, and from appropriate HIV-negative controls. The ACSR was established by the National Cancer Institute (NCI) in 1994 to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated clinical information from patients with HIV-associated malignancies to the scientific research community-at-large.

UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland – and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.